Bridgewater Associates - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.

Quarter-by-quarter ownership
Bridgewater Associates ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q4 2023$508,566
+25.3%
10,635
-6.6%
0.00%
+50.0%
Q3 2023$406,018
-26.4%
11,389
-4.8%
0.00%
-33.3%
Q2 2023$551,807
+0.7%
11,962
-12.5%
0.00%0.0%
Q1 2023$548,08713,6680.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2023
NameSharesValueWeighting ↓
First Light Asset Management, LLC 217,459$24,760,0001.64%
Motley Fool Asset Management LLC 152,326$17,344,0001.25%
Rock Springs Capital Management LP 450,000$51,237,0001.12%
AtonRa Partners 21,017$2,393,0001.07%
SECTORAL ASSET MANAGEMENT INC 112,200$12,775,0000.97%
EMERALD ADVISERS, LLC 228,368$26,002,0000.94%
EMERALD MUTUAL FUND ADVISERS TRUST 239,023$27,215,0000.90%
FEDERATED HERMES, INC. 3,912,408$445,467,0000.86%
HealthCor Management, L.P. 207,610$23,638,0000.84%
Atika Capital Management LLC 66,000$7,515,0000.65%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders